Glaukos (NYSE:GKOS) will be posting its quarterly earnings results after the market closes on Wednesday, February 28th.
Shares of Glaukos (GKOS) opened at $31.23 on Wednesday. The firm has a market cap of $1,073.95, a price-to-earnings ratio of -780.55, a price-to-earnings-growth ratio of 45.03 and a beta of 1.21. Glaukos has a 12 month low of $23.08 and a 12 month high of $52.49.
A number of equities research analysts have weighed in on the stock. BMO Capital Markets reiterated a “buy” rating on shares of Glaukos in a research note on Monday, December 11th. Cantor Fitzgerald set a $48.00 price objective on shares of Glaukos and gave the company a “buy” rating in a research report on Wednesday, January 10th. Zacks Investment Research downgraded shares of Glaukos from a “hold” rating to a “sell” rating in a research report on Tuesday, February 13th. ValuEngine downgraded shares of Glaukos from a “hold” rating to a “sell” rating in a research report on Monday, February 5th. Finally, Stephens reissued an “overweight” rating and set a $40.00 price objective (down previously from $47.00) on shares of Glaukos in a research report on Monday, November 13th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $44.86.
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.